Gerardo BottiFederica FratangeloMargherita CerroneGiuseppina LiguoriMonica CantileAnna Maria AnnicielloStefania ScalaCrescenzo D’AlterioC TrimarcoAngela IanaroGiuseppe CirinoCorrado CaracòMaria ColombinoGiuseppe PalmieriStefano PepePaolo A. AsciertoFrancesco SabbatinoGiosuè Scognamiglio
COX-2 expression correlates with and modulates PD-L1 expression in melanoma cells. These findings have clinical relevance since they provide a rationale to implement novel clinical trials to test COX-2 inhibition as a potential treatment to prevent melanoma progression and immune evasion as well as to enhance the anti-tumor activity of PD-1/PD-L1 based immunotherapy for the treatment of melanoma patients with or without BRAF/NRAS mutations.
Botti, GerardoFratangelo, FedericaCerrone, MargheritaLiguori, GiuseppinaCantile, MonicaAnniciello, AnnaScala, StefaniaDâAlterio, CrescenzoTrimarco, ChiaraIanaro, AngelaCirino, GiuseppeCaracò, CorradoColombino, MariaPalmieri, GiuseppePepe, StefanoAscierto, PaoloSabbatino, FrancescoGiosuè Scognamiglio
Botti, GerardoFratangelo, FedericaCerrone, MargheritaLiguori, GiuseppinaCantile, MonicaAnniciello, AnnaScala, StefaniaDâAlterio, CrescenzoTrimarco, ChiaraIanaro, AngelaCirino, GiuseppeCaracò, CorradoColombino, MariaPalmieri, GiuseppePepe, StefanoAscierto, PaoloSabbatino, FrancescoGiosuè Scognamiglio
Fangran LiuJiao LiuJinguo ZhangJimin ShiLü GuiGuoxiong Xu
Zhidan HuaXian-Bing LiuJianhui ShengChao LiPing LiXiuqin CaiZhiqiang Han
Goran MicevicDurga ThakralMeaghan K. McGearyMarcus Bosenberg